Free Trial

Upstream Bio (UPB) Competitors

Upstream Bio logo
$11.13 +0.34 (+3.15%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$11.22 +0.09 (+0.77%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UPB vs. BHC, GMTX, APLS, ARWR, VCEL, TWST, KNSA, RXRX, DNLI, and NAMS

Should you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), Twist Bioscience (TWST), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

Upstream Bio vs. Its Competitors

Bausch Health Cos (NYSE:BHC) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Upstream Bio has a net margin of 0.00% compared to Bausch Health Cos' net margin of -0.41%. Upstream Bio's return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Cos-0.41% -540.45% 5.26%
Upstream Bio N/A N/A N/A

Bausch Health Cos has higher revenue and earnings than Upstream Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Cos$9.63B0.27-$46M-$0.11-64.64
Upstream Bio$2.37M252.61-$62.81MN/AN/A

78.7% of Bausch Health Cos shares are held by institutional investors. 8.1% of Bausch Health Cos shares are held by company insiders. Comparatively, 13.6% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bausch Health Cos currently has a consensus price target of $7.42, indicating a potential upside of 4.31%. Upstream Bio has a consensus price target of $56.50, indicating a potential upside of 407.64%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Upstream Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Bausch Health Cos had 9 more articles in the media than Upstream Bio. MarketBeat recorded 10 mentions for Bausch Health Cos and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.93 beat Bausch Health Cos' score of 0.61 indicating that Upstream Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Cos
1 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upstream Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Upstream Bio beats Bausch Health Cos on 8 of the 13 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPB vs. The Competition

MetricUpstream BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$580.43M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E RatioN/A21.3126.1719.90
Price / Sales252.61278.47413.55113.66
Price / CashN/A41.4736.1356.90
Price / Book1.277.518.025.38
Net Income-$62.81M-$55.05M$3.15B$248.50M
7 Day Performance1.74%2.07%1.48%2.06%
1 Month Performance2.68%4.84%3.66%4.86%
1 Year PerformanceN/A5.37%34.68%20.24%

Upstream Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPB
Upstream Bio
1.8585 of 5 stars
$11.13
+3.2%
$56.50
+407.6%
N/A$580.43M$2.37M0.0038
BHC
Bausch Health Cos
3.2418 of 5 stars
$6.11
-1.1%
$7.42
+21.4%
+0.0%$2.29B$9.63B-55.5520,700
GMTX
Gemini Therapeutics
N/A$51.61
+3.0%
N/A+10.0%$2.24BN/A-51.6130High Trading Volume
APLS
Apellis Pharmaceuticals
4.5337 of 5 stars
$17.62
-0.4%
$40.05
+127.3%
-49.1%$2.22B$781.37M-9.84770Trending News
Analyst Forecast
Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.9354 of 5 stars
$15.51
+1.2%
$43.71
+181.8%
-33.0%$2.12B$3.55M-11.08400Positive News
VCEL
Vericel
2.8722 of 5 stars
$41.80
-0.5%
$61.14
+46.3%
-8.0%$2.12B$237.22M1,393.80300
TWST
Twist Bioscience
4.4187 of 5 stars
$35.33
+2.0%
$50.40
+42.7%
-20.4%$2.08B$312.97M-10.87990News Coverage
Positive News
KNSA
Kiniksa Pharmaceuticals International
3.7148 of 5 stars
$28.72
+1.0%
$38.80
+35.1%
+48.7%$2.08B$481.17M-114.88220
RXRX
Recursion Pharmaceuticals
1.8974 of 5 stars
$4.83
-4.0%
$7.00
+44.9%
-27.2%$2.04B$58.84M-2.73400
DNLI
Denali Therapeutics
4.5657 of 5 stars
$13.62
-1.9%
$33.71
+147.5%
-31.5%$2.02B$330.53M-5.10430
NAMS
NewAmsterdam Pharma
2.9978 of 5 stars
$18.21
+1.4%
$42.89
+135.5%
-6.6%$2.02B$45.56M-9.694

Related Companies and Tools


This page (NASDAQ:UPB) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners